Immunotherapy for infectious diseases in haematological immunocompromise

British Journal of Haematology

Volumn 177, Issue 3, 2017, Pages 348-356

  Cutino Moguel, Maria Teresa ^a   Eades, Chris ^b   Rezvani, Katayoun ^c   Armstrong James, Darius ^d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

antibodies; cell therapy; cytokines; immunotherapy; Infection

Indexed keywords

ANTHRACYCLINE DERIVATIVE; IMMUNOGLOBULIN; MEDI 8897; MONOCLONAL ANTIBODY; MOTAVIZUMAB; PALIVIZUMAB; PROBIOTIC AGENT; RECOMBINANT COLONY STIMULATING FACTOR; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; TEFIBAZUMAB; UNCLASSIFIED DRUG; VACCINE; COLONY STIMULATING FACTOR; CYTOKINE;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CHRONIC GRANULOMATOUS DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; GRANULOCYTE TRANSFUSION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; INFECTION; INFLUENZA; INNATE IMMUNITY; INTESTINE FLORA; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LYMPHOMA; MUCOSAL IMMUNITY; MULTICENTER STUDY (TOPIC); NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW (TOPIC); VIRUS INFECTION; VIRUS REACTIVATION; BIOLOGICAL THERAPY; COMPLICATION; HEMATOLOGIC DISEASES; IMMUNOLOGY; OPPORTUNISTIC INFECTIONS; PROCEDURES; TRENDS;

CELL- AND TISSUE-BASED THERAPY; COLONY-STIMULATING FACTORS; CYTOKINES; HEMATOLOGIC DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS; IMMUNOTHERAPY; OPPORTUNISTIC INFECTIONS; PROBIOTICS; VACCINES;

EID: 85016570249     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14595     Document Type: Review

References (95)

1. Abdolrasouli, A., Rhodes, J., Beale, M.A., Hagen, F., Rogers, T.R., Chowdhary, A., Meis, J.F., Armstrong-James, D. & Fisher, M.C. (2015) Genomic context of azole resistance mutations in Aspergillus fumigatus determined using whole-genome sequencing. mBio, 6, e00536–15.
2. Abougergi, M.S. & Kwon, J.H. (2011) Intravenous immunoglobulin for the treatment of clostridium difficile infection: a review. Digestive Diseases and Sciences, 56, 19–26.
3. American Academy of Pediatrics (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics, 134, 415–420.
4. Appelbaum, F.R. (2009) Optimising the conditioning regimen for acute myeloid leukaemia. Best practice & research. Clinical haematology, 22, 543–550.
5. Armstrong-James, D., Teo, I.A., Shrivastava, S., Petrou, M.A., Taube, D., Dorling, A. & Shaunak, S. (2010) Exogenous interferon-γ immunotherapy for invasive fungal infections in kidney transplant patients. American Journal of Transplantation, 10, 1796–1803.
6. Blaes, A.H., Cao, Q., Wagner, J.E., Young, J.-A.H., Weisdorf, D.J. & Brunstein, C.G. (2010) Monitoring and preemptive rituximab therapy for epstein-barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biology of Blood and Marrow Transplantation, 16, 287–291.
7. Blaise, D. & Castagna, L. (2012) Do different conditioning regimens really make a difference? Hematology/the Education Program of the American Society of Hematology, 2012, 237–245.
8. Blaser, M.J. (2014) The microbiome revolution. Journal of Clinical Investigation, 124, 4162–4165.
9. Blyth, E., Clancy, L., Simms, R., Ma, C.K.K., Burgess, J., Deo, S., Byth, K., Dubosq, M.C., Shaw, P.J., Micklethwaite, K.P. & Gottlieb, D.J. (2013) Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood, 121, 3745–3758.
10. Bo, L., Wang, F., Zhu, J., Li, J. & Deng, X. (2011) Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Critical Care, 15, R58.
11. Bouzani, M., Ok, M., McCormick, A., Ebel, F., Kurzai, O., Morton, C.O., Einsele, H. & Loeffler, J. (2011) Human NK cells display important antifungal activity against aspergillus fumigatus, which is directly mediated by IFN-γ release. Journal of immunology (Baltimore, Md. : 1950), 187, 1369–1376.
12. Bowden, R.A., Fisher, L.D., Rogers, K., Cays, M. & Meyers, J.D. (1991) Cytomegalovirus (Cmv)-specific intravenous immunoglobulin for the prevention of primary cmv infection and disease after marrow transplant. Journal of Infectious Diseases, 164, 483–487.
13. Bozza, S., Perruccio, K., Montagnoli, C., Gaziano, R., Bellocchio, S., Burchielli, E., Nkwanyuo, G., Pitzurra, L., Velardi, A. & Romani, L. (2003) A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood, 102, 3807–3814.
14. Budde, L.E., Berger, C., Lin, Y., Wang, J., Lin, X., Frayo, S.E., Brouns, S.A., Spencer, D.M., Till, B.G., Jensen, M.C., Riddell, S.R. & Press, O.W. (2013) Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS ONE, 8, e82742.
15. Caliendo, A.M., Gilbert, D.N., Ginocchio, C.C., Hanson, K.E., May, L., Quinn, T.C., Tenover, F.C., Alland, D., Blaschke, A.J., Bonomo, R.A., Carroll, K.C., Ferraro, M.J., Hirschhorn, L.R., Joseph, W.P., Karchmer, T., MacIntyre, A.T., Reller, L.B. & Jackson, A.F. (2013) Better tests, better care: improved diagnostics for infectious diseases. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 57, S139–S170.
16. Carbonell-Estrany, X., Simões, E.A.F., Dagan, R., Hall, C.B., Harris, B., Hultquist, M., Connor, E.M. & Losonsky, G.A (2010) Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics, 125, e35–e51.
17. Chen, Z., Moayeri, M. & Purcell, R. (2011) Monoclonal antibody therapies against anthrax. Toxins, 3, 1004–1019.
18. Cheng, M., Chen, Y., Xiao, W., Sun, R. & Tian, Z. (2013) NK cell-based immunotherapy for malignant diseases. Cellular & molecular immunology, 10, 230–252.
19. Chirmule, N., Propert, K., Magosin, S., Qian, Y., Qian, R. & Wilson, J. (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene therapy, 6, 1574–1583.
20. Cobbold, M., Khan, N., Pourgheysari, B., Tauro, S., McDonald, D., Osman, H., Assenmacher, M., Billingham, L., Steward, C., Crawley, C., Olavarria, E., Goldman, J., Chakraverty, R., Mahendra, P., Craddock, C. & Moss, P.A.H. (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. The Journal of experimental medicine, 202, 379–386.
21. Cristófani, L.M., Weinberg, A., Peixoto, V., Boas, L.S., Marques, H.H., Maluf Júnior, P.T., Pannuti, C., Oselka, G.W., Amato Neto, V. & Odone-Filho, V. (1991) Administration of live attenuated varicella vaccine to children with cancer before starting chemotherapy. Vaccine, 9, 873–876.
22. Deitsch, K.W., Lukehart, S.A. & Stringer, J.R. (2009) Common strategies for antigenic variation by bacterial, fungal and protozoan pathogens. Nature reviews. Microbiology, 7, 493–503.
23. Delsing, C.E., Gresnigt, M.S., Leentjens, J., Preijers, F., Frager, F.A., Kox, M., Monneret, G., Venet, F., Bleeker-Rovers, C.P., van de Veerdonk, F.L., Pickkers, P., Pachot, A., Kullberg, B.J. & Netea, M.G. (2014) Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC infectious diseases, 14, 166.
24. Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A.G., Grilley, B., Liu, H., Cruz, C.R., Savoldo, B., Gee, A.P., Schindler, J., Krance, R.A., Heslop, H.E., Spencer, D.M., Rooney, C.M. & Brenner, M.K. (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. The New England journal of medicine, 365, 1673–1683.
25. Dignani, M.C., Rex, J.H., Chan, K.W., Dow, G., DeMagalhaes-Silverman, M., Maddox, A., Walsh, T. & Anaissie, E. (2005) Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer, 104, 199–204.
26. Eberl, G. & Boneca, I.G. (2010) Bacteria and MAMP-induced morphogenesis of the immune system. Current Opinion in Immunology, 22, 448–454.
27. Einsele, H., Roosnek, E., Rufer, N., Sinzger, C., Riegler, S., Löffler, J., Grigoleit, U., Moris, A., Rammensee, H.G., Kanz, L., Kleihauer, A., Frank, F., Jahn, G. & Hebart, H. (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood, 99, 3916–3922.
28. Emery, V., Zuckerman, M., Jackson, G., Aitken, C., Osman, H., Pagliuca, A., Potter, M., Peggs, K. & Clark, A. (2013) Management of cytomegalovirus infection in haemopoietic stem cell transplantation. British Journal of Haematology, 162, 25–39.
29. Estcourt, L.J., Stanworth, S.J., Hopewell, S., Doree, C., Trivella, M. & Massey, E. (2016) Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction. Cochrane Database of Systematic Reviews, 4, CD005339.
30. Fausther-Bovendo, H. & Kobinger, G.P. (2014) Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? Human Vaccines and Immunotherapeutics, 10, 2875–2884.
31. Francis, T. & Shope, R.E. (1936) Neutralization tests with sera of convalescent or immunized animals and the viruses of swine and human influenza. The Journal of experimental medicine, 63, 645–653.
32. François, B., Luyt, C.-E., Dugard, A., Wolff, M., Diehl, J.-L., Jaber, S., Forel, J.-M., Garot, D., Kipnis, E., Mebazaa, A., Misset, B., Andremont, A., Ploy, M.-C., Jacobs, A., Yarranton, G., Pearce, T., Fagon, J.-Y. & Chastre, J. (2012) Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Critical care medicine, 40, 2320–2326.
33. Freyer, G., Jovenin, N., Yazbek, G., Villanueva, C., Hussain, A., Berthune, A., Rotarski, M., Simon, H., Boulanger, V., Hummelsberger, M. & Falandry, C. (2013) Granocyte-colony stimulating factor (G-CSF) has significant efficacy as secondary prophylaxis of chemotherapy-induced neutropenia in patients with solid tumors: results of a prospective study. Anticancer Research, 33, 301–308.
34. Frogel, M., Nerwen, C., Cohen, A., VanVeldhuisen, P., Harrington, M. & Boron, M. (2008) Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. Journal of perinatology : official journal of the California Perinatal Association, 28, 511–517.
35. Gillespie, G.M., Wills, M.R., Appay, V., O'Callaghan, C., Murphy, M., Smith, N., Sissons, P., Rowland-Jones, S., Bell, J.I. & Moss, P.A (2000) Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. Journal of virology, 74, 8140–8150.
36. Griffiss, J.M. (1975) Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera. Journal of immunology (Baltimore, Md. : 1950), 114, 1779–1784.
37. Heslop, H.E., Ng, C.Y., Li, C., Smith, C.A., Loftin, S.K., Krance, R.A., Brenner, M.K. & Rooney, C.M. (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature medicine, 2, 551–555.
38. Ho, P., Sherman, P. & Grigg, A. (2012) Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia. European Journal of Haematology, 88, 416–421.
39. Hung, I.F.N., To, K.K.W., Lee, C.-K., Lee, K.-L., Yan, W.-W., Chan, K., Chan, W.-M., Ngai, C.-W., Law, K.-I., Chow, F.-L., Liu, R., Lai, K.-Y., Lau, C.C.Y., Liu, S.-H., Chan, K.-H., Lin, C.-K. & Yuen, K.-Y. (2013) Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest, 144, 464–473.
40. Jeong, K.-I., Tzipori, S. & Sheoran, A.S. (2010) Shiga toxin 2-specific but not shiga toxin 1-specific human monoclonal antibody protects piglets challenged with enterohemorrhagic Escherichia coli producing shiga toxin 1 and shiga toxin 2. The Journal of infectious diseases, 201, 1081–1083.
41. Jiang, L., Fantoni, G., Couzens, L., Gao, J., Plant, E., Ye, Z., Eichelberger, M.C. & Wan, H. (2016) Comparative efficacy of monoclonal antibodies that bind to different epitopes of the 2009 pandemic H1N1 influenza virus neuraminidase. Journal of virology, 90, 117–128.
42. Khanna, N., Stuehler, C., Conrad, B., Lurati, S., Krappmann, S., Einsele, H., Berges, C., Topp, M.S. & Dc, W. (2011) Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154 Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood, 118, 1121–1131.
43. Kontoyiannis, D.P., Marr, K.A., Park, B.J., Alexander, B.D., Anaissie, E.J., Walsh, T.J., Ito, J., Andes, D.R., Baddley, J.W., Brown, J.M., Brumble, L.M., Freifeld, A.G., Hadley, S., Herwaldt, L.A., Kauffman, C.A., Knapp, K., Lyon, G.M., Morrison, V.A., Papanicolaou, G., Patterson, T.F., Perl, T.M., Schuster, M.G., Walker, R., Wannemuehler, K.A., Wingard, J.R., Chiller, T.M. & Pappas, P.G. (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50, 1091–1100.
44. Kumaresan, P.R., Manuri, P.R., Albert, N.D., Maiti, S., Singh, H., Mi, T., Roszik, J., Rabinovich, B., Olivares, S., Krishnamurthy, J., Zhang, L., Najjar, A.M., Huls, M.H., Lee, D.A., Champlin, R.E., Kontoyiannis, D.P. & Cooper, L.J. (2014) Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A, 111, 10660–10665.
45. Kussmaul, S.C., Horn, B.N., Dvorak, C.C., Abramovitz, L., Cowan, M.J. & Weintrub, P.S. (2010) Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone marrow transplantation, 45, 1602–1606.
46. Leen, A.M., Myers, G.D., Sili, U., Huls, M.H., Weiss, H., Leung, K.S., Carrum, G., Krance, R.A., Chang, C., Molldrem, J.J., Gee, A.P., Brenner, M.K., Heslop, H.E., Rooney, C.M. & Bollard, C.M. (2006) Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature Medicine, 12, 1160–1166.
47. Ljungman, P., Wiklund-Hammarsten, M., Duraj, V., Hammarstrom, L., Lonnqvist, B., Paulin, T., Ringden, O., Sullivan Pepe, M. & Gahrton, G. (1990) Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. Journal of Infectious Diseases, 162, 496–500.
48. Ljungman, P., Duraj, V. & Magnius, L. (1991) Response to immunization against polio after allogeneic marrow transplantation. Bone marrow transplantation, 7, 89–93.
49. Ljungman, P., Lewensohn-Fuchs, I., Hammarström, V., Aschan, J., Brandt, L., Bolme, P., Lönnqvist, B., Johansson, N., Ringdén, O. & Gahrton, G. (1994) Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood, 84, 657–663.
50. Lowy, I., Molrine, D.C.D.D.C.D., Leav, B.B.A., Blair, B.M., Baxter, R., Gerding, D.N., Nichol, G., Thomas, W.D., Leney, M., Sloan, S., Hay, C.A. & Ambrosino, D.M. (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. The New England journal of Medicine, 362, 197–205.
51. Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J.K., Cleary, P., Khaw, F.-M., Lim, W.S., Makki, S., Rooney, K.D., Nguyen-Van-Tam, J.S. & Beck, C.R. & Convalescent Plasma Study Group (2015) The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. The Journal of infectious diseases, 211, 80–90.
52. Massey, E., Paulus, U., Doree, C. & Stanworth, S. (2009) Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database of Systematic Reviews, 1, CD005341. doi: 10.1002/14651858.CD005341.pub2.
53. Mehta, H.M., Malandra, M. & Corey, S.J. (2015) G-CSF and GM-CSF in neutropenia. Journal of Immunology, 195, 1341–1349.
54. Menger, L., Gouble, A., Marzolini, M.A.V., Pachnio, A., Bergerhoff, K., Henry, J.Y., Smith, J., Pule, M., Moss, P., Riddell, S.R., Quezada, S.A. & Peggs, K.S. (2015) TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. Blood, 126, 2781–2789.
55. Mhaskar, R., Clark, O.A.C., Lyman, G., Engel Ayer Botrel, T., Morganti Paladini, L. & Djulbegovic, B. (2014) Colony-stimulating factors for chemotherapy-induced febrile neutropenia. The Cochrane database of systematic reviews, 10, CD003039.
56. Page, A.V. & Liles, W.C. (2011) Colony-stimulating factors in the prevention and management of infectious diseases. Infectious Disease Clinics of North America, 25, 803–817.
57. Papadopoulou, A., Gerdemann, U., Katari, U.L., Tzannou, I., Liu, H., Martinez, C., Leung, K., Carrum, G., Gee, A.P., Vera, J.F., Krance, R.A., Brenner, M.K., Rooney, C.M., Heslop, H.E. & Leen, A.M. (2014) Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Science Translational Medicine, 6, 1–12.
58. Park, S.J., Hughes, M.A., Burdick, M., Strieter, R.M. & Mehrad, B. (2009) Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis. Journal of immunology (Baltimore, Md. : 1950), 182, 4306–4312.
59. Parker, A., Bowles, K., Bradley, J.A., Emery, V., Featherstone, C., Gupte, G., Marcus, R., Parameshwar, J., Ramsay, A. & Newstead, C. (2010) Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. British Journal of Haematology, 149, 693–705.
60. Patterson, T.F., Iii, R.T., Denning, D.W., Fishman, J.A., Hadley, S., Herbrecht, R., Kontoyiannis, D.P., Marr, K.A., Morrison, V.A., Nguyen, M.H., Segal, B.H., Steinbach, W.J., Stevens, D.A., Walsh, T.J. & Wingard, J.R. (2016) Practice Guidelines for the Diagnosis and Management of Aspergillosis : 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 63, 1–60.
61. Patti, J.M. (2004) A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine, 22, S39–S43.
62. Perruccio, K., Tosti, A., Burchielli, E., Topini, F., Ruggeri, L., Capanni, M., Urbani, E., Mancusi, A., Aversa, F., Martelli, M.F., Romani, L. & Velardi, A. (2005) Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood, 106, 4397–4406.
63. Phillips, R., Hancock, B., Graham, J., Bromham, N., Jin, H. & Berendse, S. (2012) Prevention and management of neutropenic sepsis in patients with cancer: summary of NICE guidance. BMJ, 345, e5368–e5368.
64. Pirofski, L.A. & Casadevall, A. (2008) The damage-response framework of microbial pathogenesis and infectious diseases. Advances in Experimental Medicine and Biology, 635, 135–146.
65. Price, T.H., Boeckh, M., Harrison, R.W., McCullough, J., Ness, P.M., Strauss, R.G., Nichols, W.G., Hamza, T.H., Cushing, M.M., King, K.E., Young, J.A.H., Williams, E., McFarland, J., Chakrabarty, J.H., Sloan, S.R., Friedman, D., Parekh, S., Sachais, B.S., Kiss, J.E. & Assmann, S.F. (2015) Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. In Blood, 126, 2153–2161.
66. Reid, G., Jass, J., Sebulsky, M.T. & McCormick, J.K. (2003) Potential uses of probiotics in clinical practice. Clinical Microbiology Reviews, 16, 658–672.
67. Remberger, M., Naseh, N., Aschan, J., Barkholt, L., LeBlanc, K., Svennberg, P. & Ringdén, O. (2003) G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone marrow transplantation, 32, 217–223.
68. Romani, L. (2011) Immunity to fungal infections. Nature reviews. Immunology, 11, 275–288.
69. Rosenberg, P.S., Zeidler, C., Bolyard, A.A., Alter, B.P., Bonilla, M.A., Boxer, L.A., Dror, Y., Kinsey, S., Link, D.C., Newburger, P.E., Shimamura, A., Welte, K. & Dale, D.C. (2010) Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. British journal of haematology, 150, 196–199.
70. Rubin, L.G., Levin, M.J., Ljungman, P., Davies, E.G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H. & Kang, I. & Infectious Diseases Society of America (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 58, 309–318.
71. Rupp, M.E., Holley, H.P., Lutz, J., Dicpinigaitis, P.V., Woods, C.W., Levine, D.P., Veney, N. & Fowler, V.G. (2007) Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrobial Agents and Chemotherapy, 51, 4249–4254.
72. Safdar, A., Rodriguez, G., Ohmagari, N., Kontoyiannis, D.P., Rolston, K. V, Raad, I.I. & Champlin, R.E. (2005) The safety of interferon-γ-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer (New York, NY, United States), 103, 731–739.
73. Salminen, M.K., Tynkkynen, S., Rautelin, H., Saxelin, M., Vaara, M., Ruutu, P., Sarna, S., Valtonen, V. & Järvinen, A. (2002) Lactobacillus Bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clinical Infectious Diseases, 35, 1155–1160.
74. Sathish, J.G., Sethu, S., Bielsky, M.-C., de Haan, L., French, N.S., Govindappa, K., Green, J., Griffiths, C.E.M., Holgate, S., Jones, D., Kimber, I., Moggs, J., Naisbitt, D.J., Pirmohamed, M., Reichmann, G., Sims, J., Subramanyam, M., Todd, M.D., Van Der Laan, J.W., Weaver, R.J. & Park, B.K. (2013) Challenges and approaches for the development of safer immunomodulatory biologics. Nature reviews. Drug discovery, 12, 306–324.
75. Schelenz, S., Nwaka, D. & Hunter, P.R. (2013) Longitudinal surveillance of bacteraemia in haematology and oncology patients at a uk cancer centre and the impact of ciprofloxacin use on antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 68, 1431–1438.
76. Secher, T., Fauconnier, L., Szade, A., Rutschi, O., Fas, S.C., Ryffel, B. & Rudolf, M.P. (2011) Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection. Journal of Antimicrobial Chemotherapy, 66, 1100–1109.
77. Segal, B.H. & Romani, L.R. (2009) Invasive aspergillosis in chronic granulomatous disease. Medical mycology : official publication of the International Society for Human and Animal Mycology, 47, S282–S290.
78. Seidel, M.G., Peters, C., Wacker, A, Northoff, H., Moog, R., Boehme, A., Silling, G., Grimminger, W. & Einsele, H. (2008) Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone marrow transplantation, 42, 679–684.
79. Shah, S.S., Hall, M., Srivastava, R., Subramony, A. & Levin, J.E. (2009) Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clinical Infectious Diseases, 49, 1369–1376.
80. Smith, D.J. (2004) Mapping the antigenic and genetic evolution of influenza virus. Science, 305, 371–376.
81. Smith, T.J., Bohlke, K., Lyman, G.H., Carson, K.R., Crawford, J., Cross, S.J., Goldberg, J.M., Khatcheressian, J.L., Leighl, N.B., Perkins, C.L., Somlo, G., Wade, J.L., Wozniak, A. J. & Armitage, J.O. (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 33, 3199–3212.
82. Stillerman, M., Marks, H.H. & Thalhimer, W. (1944) Prophylaxis of measles with convalescent serum: principal factors influencing the results. American Journal of Diseases of Children, 67, 1–14.
83. Straathof, K.C., Pulè, M.A., Yotnda, P., Dotti, G., Vanin, E.F., Brenner, M.K., Heslop, H.E., Spencer, D.M. & Rooney, C.M. (2005) An inducible caspase 9 safety switch for T-cell therapy. Blood, 105, 4247–4254.
84. Stuehler, C., Khanna, N., Bozza, S., Zelante, T., Moretti, S., Kruhm, M., Conrad, B., Worschech, E., Stevanovic, S., Krappmann, S., Einsele, H., Latgé, J., Loeffler, J., Romani, L., Topp, M.S., Dc, W., Lurati, S. & Latge, J. (2011) Cross-protective T H 1 immunity against Aspergillus fumigatus and Candida albicans, Blood, 117, 5881–5891.
85. Styczynski, J., Gil, L., Tridello, G., Ljungman, P., Donnelly, J.P., van der Velden, W., Omar, H., Martino, R., Halkes, C., Faraci, M., Theunissen, K., Kalwak, K., Hubacek, P., Sica, S., Nozzoli, C., Fagioli, F., Matthes, S., Diaz, M. A, Migliavacca, M., Balduzzi, A., Tomaszewska, A, Camara Rde, L., van Biezen, A., Hoek, J., Iacobelli, S., Einsele, H. & Cesaro, S. for the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. (2013) Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Gro. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 57, 794–802.
86. Tischer, S., Dieks, D., Sukdolak, C., Bunse, C., Figueiredo, C., Immenschuh, S., Borchers, S., Stripecke, R., Maecker-Kolhoff, B., Blasczyk, R. & Eiz-Vesper, B. (2014) Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches. Journal of Immunological Methods, 408, 101–113.
87. Tobita, K., Yanaka, H. & Otani, H. (2010) Lactobacillus crispatus KT-11 enhances intestinal immune functions in C3H/HeN mice. Journal of nutritional science and vitaminology, 56, 441–445.
88. Walsh, T.J., Anaissie, E.J., Denning, D.W., Herbrecht, R., Kontoyiannis, D.P., Marr, K.A., Morrison, V.A., Segal, B.H., Steinbach, W.J., Stevens, D.A., vanBurik, J.-A., Wingard, J.R. & Patterson, T.F. & Infectious Diseases Society of America (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 46, 327–360.
89. Walter, E.A, Greenberg, P.D., Gilbert, M.J., Finch, R.J., Watanabe, K.S., Thomas, E.D. & Riddell, S.R. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. The New England journal of medicine, 333, 1038–1044.
90. Wan, L., Zhang, Y., Lai, Y., Jiang, M., Song, Y., Zhou, J., Zhang, Z., Duan, X., Fu, Y., Liao, L. & Wang, C. (2015) Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33, 3999.
91. Winsnes, R. (1978) Efficacy of zoster immunoglobulin in prophylaxis of varicella in high-risk patients. Acta Paediatr Scand, 67, 77–82.
92. Winston, D.J., Ho, W.G., Bartoni, K. & Champlin, R.E. (1993) Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone marrow transplantation, 12, 283–288.
93. World Health Organization (2014) The evolving threat of antimicrobial resistance: Options for action. WHO Publications, Geneva, Switzerland, 1–119.
94. Wrammert, J., Smith, K., Miller, J., Langley, W.A., Kokko, K., Larsen, C., Zheng, N.-Y., Mays, I., Garman, L., Helms, C., James, J., Air, G.M., Capra, J.D., Ahmed, R. & Wilson, P.C. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature, 453, 667–671.
95. Zein, E.F., Karaa, S., Chemaly, A., Saidi, I. & Rohban, R. (2008) Lactobacillus rhamnosus septicemia in a diabetic patient associated with probiotic use a case report. Annales de Biologie Clinique, 66, 195–198.